ASH 2019 | ELEVATE-TN: approval of acalabrutinib for adult CLL
Jeff Sharman, MD, Willamette Valley Cancer Institute, Eugene, OR, discusses the interim results for the phase III ELEVATE-TN study (NCT02475681), which evaluated the efficacy and safety of acalabrutinib combined with obinutuzumab or alone versus obinutuzumab plus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia (CLL). The results showed that both acalabrutinib combined with obinutuzumab and acalabrutinib monotherapy significantly improved progression-free survival, with tolerable safety. Dr Sharman highlights the recent approval of acalabrutinib for adults with CLL or small lymphocytic lymphoma (SLL) in the United States. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
